Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 19877 | 422 | 33.3 | 82% |
Classes in level above (level 2) |
| ID, lev. above |
Publications | Label for level above |
|---|---|---|
| 222 | 19941 | LYMPHANGIOGENESIS//ANGIOGENESIS//ENDOSTATIN |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | DIARYLAMIDE | Author keyword | 21 | 90% | 2% | 9 |
| 2 | VEGFR 2 INHIBITOR | Author keyword | 15 | 88% | 2% | 7 |
| 3 | KDR KINASE | Author keyword | 13 | 80% | 2% | 8 |
| 4 | DIARYLUREA | Author keyword | 13 | 69% | 3% | 11 |
| 5 | ABT 869 | Author keyword | 8 | 70% | 2% | 7 |
| 6 | SORAFENIB ANALOGS | Author keyword | 8 | 100% | 1% | 5 |
| 7 | KDR INHIBITOR | Author keyword | 7 | 67% | 1% | 6 |
| 8 | A375P | Author keyword | 6 | 71% | 1% | 5 |
| 9 | VEGFR 2 | Author keyword | 5 | 13% | 9% | 36 |
| 10 | ATP COMPETITIVE KINASE INHIBITORS | Author keyword | 4 | 67% | 1% | 4 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | DIARYLAMIDE | 21 | 90% | 2% | 9 | Search DIARYLAMIDE | Search DIARYLAMIDE |
| 2 | VEGFR 2 INHIBITOR | 15 | 88% | 2% | 7 | Search VEGFR+2+INHIBITOR | Search VEGFR+2+INHIBITOR |
| 3 | KDR KINASE | 13 | 80% | 2% | 8 | Search KDR+KINASE | Search KDR+KINASE |
| 4 | DIARYLUREA | 13 | 69% | 3% | 11 | Search DIARYLUREA | Search DIARYLUREA |
| 5 | ABT 869 | 8 | 70% | 2% | 7 | Search ABT+869 | Search ABT+869 |
| 6 | SORAFENIB ANALOGS | 8 | 100% | 1% | 5 | Search SORAFENIB+ANALOGS | Search SORAFENIB+ANALOGS |
| 7 | KDR INHIBITOR | 7 | 67% | 1% | 6 | Search KDR+INHIBITOR | Search KDR+INHIBITOR |
| 8 | A375P | 6 | 71% | 1% | 5 | Search A375P | Search A375P |
| 9 | VEGFR 2 | 5 | 13% | 9% | 36 | Search VEGFR+2 | Search VEGFR+2 |
| 10 | ATP COMPETITIVE KINASE INHIBITORS | 4 | 67% | 1% | 4 | Search ATP+COMPETITIVE+KINASE+INHIBITORS | Search ATP+COMPETITIVE+KINASE+INHIBITORS |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | RAF KINASE INHIBITORS | 8 | 75% | 1% | 6 |
| 2 | 1 3 4 TRIARYLPYRAZOLE SCAFFOLD | 8 | 100% | 1% | 5 |
| 3 | DIARYLAMIDES | 8 | 100% | 1% | 5 |
| 4 | TASPINE DERIVATIVES | 6 | 71% | 1% | 5 |
| 5 | ABT 869 | 6 | 50% | 2% | 8 |
| 6 | FACTOR RECEPTOR 2 INHIBITORS | 6 | 100% | 1% | 4 |
| 7 | KDR KINASE | 3 | 57% | 1% | 4 |
| 8 | DIARYLUREAS | 3 | 45% | 1% | 5 |
| 9 | ARYLPHTHALAZINES | 3 | 50% | 1% | 4 |
| 10 | VEGF RECEPTOR I | 2 | 67% | 0% | 2 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| VEGF/VEGFR Pathway Inhibitors as Anti-Angiogenic Agents: Present and Future | 2011 | 30 | 180 | 29% |
| Recent Advances in Antiangiogenic Agents with VEGFR as Target | 2011 | 7 | 111 | 56% |
| Antiangiogenic agents: an update on small molecule VEGFR inhibitors | 2007 | 51 | 145 | 36% |
| Recent Progress of Small Molecular VEGFR Inhibitors as Anticancer Agents | 2011 | 8 | 87 | 33% |
| Anti-angiogenic and anti-HER therapy | 2006 | 1 | 4 | 75% |
| Development and strategies of VEGFR-2/KDR inhibitors | 2012 | 7 | 93 | 24% |
| Recent Advances in the Development of Multi-Kinase Inhibitors | 2008 | 30 | 98 | 23% |
| VEGF receptor kinase inhibitors: phthalazines, anthranilamides and related structures | 2005 | 14 | 24 | 33% |
| Strategies for the Design of Selective Protein Kinase Inhibitors | 2008 | 12 | 23 | 22% |
| Recent developments in the discovery of protein kinase inhibitors from the urea class | 2004 | 46 | 41 | 17% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | PHARMACOGEN DRUG DEV GRP | 1 | 31% | 0.9% | 4 |
| 2 | CHEM KIN | 1 | 21% | 0.9% | 4 |
| 3 | ABBOTT ONCOL | 1 | 50% | 0.2% | 1 |
| 4 | BEIJING ACTIVE SUBSTANCE DISCOVERY DRUG | 1 | 50% | 0.2% | 1 |
| 5 | CANDIOLO CANC IRCCS | 1 | 50% | 0.2% | 1 |
| 6 | EXCELLENT INNOVAT DRUG DESIGN DISCOVERY | 1 | 50% | 0.2% | 1 |
| 7 | PHARMACOL SAFETY EVALUAT TIBETAN MED QI | 1 | 50% | 0.2% | 1 |
| 8 | SMALL MOL PROC DEV | 1 | 50% | 0.2% | 1 |
| 9 | UNIV MISSISSIPPI CANC | 1 | 50% | 0.2% | 1 |
| 10 | ORIGINAL NEW DRUGS DESIGN DISCOVERY | 1 | 17% | 0.7% | 3 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000213715 | ANILINOQUINAZOLINE//COMBI MOLECULE//CANC DRUG |
| 2 | 0.0000162242 | FLT 1//VEGF RECEPTORS//VEGF165B |
| 3 | 0.0000120622 | UNITE BIOTECHNOL BIOINGN//RECHUNITE BIOTECHNOL BIOINGN//COLCHICINE BINDING SITE LIGANDS |
| 4 | 0.0000097042 | SUNITINIB//METASTATIC RENAL CELL CARCINOMA//CARCINOMA RENAL CELL |
| 5 | 0.0000078331 | TSU 68//APATINIB//MUCOCUTANEOUS TOXICITIES |
| 6 | 0.0000077826 | PHTHALHYDRAZIDE//ONG//ORGAN NANO GRP |
| 7 | 0.0000075220 | VEMURAFENIB//B RAF//BRAF INHIBITOR |
| 8 | 0.0000074055 | FRS3//FRS2//FGFRL1 |
| 9 | 0.0000072646 | OSI 420//OSI 774//CAKI 1 RENAL CELL CARCINOMA |
| 10 | 0.0000064145 | PEMETREXED//MULTITARGETED ANTIFOLATE//NONSQUAMOUS |